Vanguard Group
PYXS icon

Vanguard Group’s Pyxis Oncology PYXS Stock Holding History

Vanguard Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.69M Buy
2,335,768
+171,806
+8% +$606K ﹤0.01% 3470
2025
Q3 		$4.8M Buy
2,163,962
+14,566
+0.7% +$21K ﹤0.01% 3295
2025
Q2 		$2.36M Sell
2,149,396
-287,332
-12% -$324K ﹤0.01% 3487
2025
Q1 		$2.39M Sell
2,436,728
-4,425
-0.2% -$5.9K ﹤0.01% 3435
2024
Q4 		$3.81M Buy
2,441,153
+8,200
+0.3% +$23.6K ﹤0.01% 3371
2024
Q3 		$8.93M Buy
2,432,953
+372,509
+18% +$1.3M ﹤0.01% 3013
2024
Q2 		$6.82M Buy
2,060,444
+659,019
+47% +$2.77M ﹤0.01% 3111
2024
Q1 		$5.97M Buy
1,401,425
+94,740
+7% +$398K ﹤0.01% 3226
2023
Q4 		$2.35M Buy
1,306,685
+166,442
+15% +$285K ﹤0.01% 3547
2023
Q3 		$2.27M Buy
1,140,243
+43,794
+4% +$101K ﹤0.01% 3535
2023
Q2 		$2.81M Buy
1,096,449
+33,900
+3% +$108K ﹤0.01% 3552
2023
Q1 		$4.26M Buy
1,062,549
+144,722
+16% +$289K ﹤0.01% 3384
2022
Q4 		$1.23M Buy
917,827
+443
+0% +$665 ﹤0.01% 3838
2022
Q3 		$1.81M Buy
917,384
+68,304
+8% +$178K ﹤0.01% 3784
2022
Q2 		$2.02M Buy
849,080
+322,771
+61% +$859K ﹤0.01% 3802
2022
Q1 		$2.13M Buy
526,309
+6,011
+1% +$43.9K ﹤0.01% 3929
2021
Q4 		$5.71M Buy
+520,298
New +$5.96M ﹤0.01% 3533

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Vanguard Group's PYXS Position: Q4 2025 in Review

Vanguard Group increased its Pyxis Oncology (PYXS) stake by 7.9% in Q4 2025, buying an estimated $606K and bringing the position to 2,335,768 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3470.

Vanguard Group first reported a position in PYXS in Q4 2021 and has held it in 17 quarters since. The position peaked at $8.93M in Q3 2024. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

  • Vanguard Group held 2,335,768 shares of Pyxis Oncology worth $2.69M as of Q4 2025.
  • Vanguard Group bought 171,806 Pyxis Oncology shares in Q4 2025, an estimated $606K.
  • Pyxis Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3470 holding.
  • Vanguard Group first reported a position in Pyxis Oncology in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Pyxis Oncology position peaked at $8.93M in Q3 2024.
  • 79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.